GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Prestige Biologics Co Ltd (XKRX:334970) » Definitions » Cash Flow from Investing

Prestige Biologics Co (XKRX:334970) Cash Flow from Investing : ₩-3,811 Mil (TTM As of Sep. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Prestige Biologics Co Cash Flow from Investing?

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

For the three months ended in Sep. 2024, Prestige Biologics Co spent ₩1,069 Mil on purchasing property, plant, equipment. It gained ₩0 Mil from selling property, plant, and equipment. It spent ₩0 Mil on purchasing business. It gained ₩0 Mil from selling business. It spent ₩0 Mil on purchasing investments. It gained ₩0 Mil from selling investments. It paid ₩199Mil for net Intangibles purchase and sale. And it paid ₩0 Mil for other investing activities. In all, Prestige Biologics Co spent ₩1,268 Mil on investment activities in financial market and operating subsidiaries for the three months ended in Sep. 2024.


Prestige Biologics Co Cash Flow from Investing Historical Data

The historical data trend for Prestige Biologics Co's Cash Flow from Investing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Prestige Biologics Co Cash Flow from Investing Chart

Prestige Biologics Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Jun23 Jun24
Cash Flow from Investing
Get a 7-Day Free Trial Premium Member Only 7,159.63 -97,910.05 -83,665.45 -19,477.12 -7,926.57

Prestige Biologics Co Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Sep23 Dec23 Mar24 Jun24 Sep24
Cash Flow from Investing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -5,384.29 1,985.18 -650.60 -3,876.85 -1,268.38

Prestige Biologics Co Cash Flow from Investing Calculation

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

If a company spends cash on property, plant and equipment (PPE), this will reduce their cash position. This is called Capital Expenditures (CPEX).

Likewise, if a company buys another company for cash, this will reduce their cash position.

Prestige Biologics Co's Cash Flow from Investing for the fiscal year that ended in Jun. 2024 is calculated as:

Prestige Biologics Co's Cash Flow from Investing for the quarter that ended in Sep. 2024 is calculated as:


Cash Flow from Investing for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩-3,811 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Prestige Biologics Co  (XKRX:334970) Cash Flow from Investing Explanation

Cash flow from investing contains nine items:

1. Purchase Of Property, Plant, Equipment:
Purchase of PPE indicates the amount used to purchase property, plant, and equipment.

Prestige Biologics Co's purchase of property, plant, equipment for the three months ended in Sep. 2024 was ₩-1,069 Mil. It means Prestige Biologics Co spent ₩1,069 Mil on purchasing property, plant, equipment.

In the capital spending for property, plant and equipment (PPE), some part of spending may be from the expansion of business. The business needs more property, plant and equipment (PPE) as it grows. Another part may be from replacement of the property, plant and equipment (PPE) of existing business. For some companies, the cash spent on replacing of the property, plant and equipment (PPE) of the existing business will be close to the depreciation of property, plant and equipment (PPE) reported in the income statement.

In Warren Buffett's definition of Owner's Earnings, he deducts the estimate of the cost of replacing the property, plant and equipment (PPE) of the existing business from cash flow from operations. The cash spent on the new property, plant, and equipment is not deducted. The reason is because these are not costs of the existing business. In his 1986 letter to shareholders, Warren Buffett wrote this about owner earnings:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume....Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

2. Sale Of Property, Plant, Equipment:
Sale of PPE indicates the amount gained from selling property, plant, and equipment.

Prestige Biologics Co's sale of property, plant, equipment for the three months ended in Sep. 2024 was ₩0 Mil. It means Prestige Biologics Co gained ₩0 Mil from selling property, plant, and equipment.

3.Purchase Of Business:
Purchase of business indicates the amount used to purchase business.

Prestige Biologics Co's purchase of business for the three months ended in Sep. 2024 was ₩0 Mil. It means Prestige Biologics Co spent ₩0 Mil on purchasing business.

4. Sale Of Business:
Sale of business indicates the amount gained from selling business.

Prestige Biologics Co's sale of business for the three months ended in Sep. 2024 was ₩0 Mil. It means Prestige Biologics Co gained ₩0 Mil from selling business.

5. Purchase Of Investment:
Purchase of Investments represents cash outflow on the purchase of investments in securities.

Prestige Biologics Co's purchase of investment for the three months ended in Sep. 2024 was ₩0 Mil. It means Prestige Biologics Co spent {stock_data.stock.currency_symbol}}0 Mil on purchasing investments.

6. Sale Of Investment:
Sale of Investments represents cash inflow on the sale of investments in securities.

Prestige Biologics Co's sale of investment for the three months ended in Sep. 2024 was ₩0 Mil. It means Prestige Biologics Co gained ₩0 Mil from selling investments.

7. Net Intangibles Purchase And Sale:
Net Intangibles purchase and sale means the net cash inflow received by a company that comes from the purchase and sale of intangibles. It equals the cash received from sale of intangibles minus the cash spent on purchasing intangibles.

Prestige Biologics Co's net Intangibles purchase and sale for the three months ended in Sep. 2024 was ₩-199 Mil. It means Prestige Biologics Co paid ₩199 Mil for net Intangibles purchase and sale.

8. Cash From Discontinued Investing Activities:
Cash from discontinued investing activities means the cash received by a company that comes from the discontinued investing activities.

Prestige Biologics Co's cash from discontinued investing activities for the three months ended in Sep. 2024 was 0 Mil. It means Prestige Biologics Co paid ₩0 Mil for discontinued investing activities.

9. Cash From Other Investing Activities:
Cash from other investing activities means the cash received by a company that comes from other investing activities.

Prestige Biologics Co's cash from other investing activities for the three months ended in Sep. 2024 was ₩-0 Mil. It means Prestige Biologics Co paid ₩0 Mil for other investing activities.


Prestige Biologics Co Cash Flow from Investing Related Terms

Thank you for viewing the detailed overview of Prestige Biologics Co's Cash Flow from Investing provided by GuruFocus.com. Please click on the following links to see related term pages.


Prestige Biologics Co Business Description

Traded in Other Exchanges
N/A
Address
197, Osongsaengmyeong 1-ro, Osong-eup, Heungdeok-gu, Chungcheongbuk-do, Cheongju-si, KOR, 28161
Prestige Biologics Co Ltd is a CDMO-dedicated company that provides solutions of development and manufacturing tasks throughout the stages from the research/development, engineering, clinical production, commercial production, clinical support, and IND & BLA filing of biopharmaceutical products. Its product candidate includes HD201 (Herceptin Biosimilar).

Prestige Biologics Co Headlines

No Headlines